Relapse rates among veterans on maintenance doses of combination buprenorphine and naloxone for opioid use disorder

• Published in: The mental health clinician 2020-05, Vol.10 (3), p.80-84
• Main Authors: Binger, Katie J, Ansara, Elayne D, Miles, Talia M, Schulte, Samantha L
• Format: Article
• Language: English
• Subjects: Original Research
• ISSN: 2168-9709; 2168-9709
• DOI: 10.9740/mhc.2020.05.080

Opioid use disorder (OUD) can cause significant morbidity and mortality with more than 115 people dying from an opioid overdose daily in the United States. Treatment with buprenorphine/naloxone (BUP/NAL) can be effective; however, there is conflicting evidence on the utility of higher doses in preventing relapse. This study was designed to assess BUP/NAL maintenance doses and the rate of relapse in veterans with OUD. Patients diagnosed with OUD who received a prescription for BUP/NAL through the substance use disorder recovery program were retrospectively evaluated. Patients were categorized into 2 treatment groups: those prescribed ≤16 mg of BUP/NAL daily and those prescribed >16 mg of BUP/NAL daily. The primary outcome was to determine rates of relapse between maintenance doses of BUP/NAL. Secondary outcomes included evaluating the difference in rates of relapse between daily versus take-home dosing, tablets versus films, time to relapse, and use of illicit substances during treatment. Patients prescribed >16 mg of BUP/NAL daily had statistically significantly lower rates of relapse compared to patients prescribed ≤16 mg of BUP/NAL daily (  = .0018). Regarding secondary outcomes, there was a statistically significant difference in time to relapse (  = .036) and dosage form (  = .0124). Difference in administration of dose and illicit substance use during treatment were not statistically significant. This study identified that rate of relapse can be lowered and time to relapse can be lengthened when doses >16 mg of BUP/NAL are prescribed in the veteran population for OUD.